Introduction {#S0001}
============

[](#FN0001) [^1]Pertussis is a highly contagious respiratory disease mainly caused by *Bordetella pertuss*is.^[1](#CIT0001),[2](#CIT0002)^ It causes uncontrollable violent coughing for long periods, most commonly affects infants and young children, and can be fatal, especially in infants up to 6 months of age.^[1](#CIT0001),[2](#CIT0002)^ Childhood immunization with whole-cell pertussis (wP) containing vaccines led to important reduction in pertussis incidence in countries that achieved high vaccine coverage.^[2](#CIT0002),[3](#CIT0003)^

However, a global reemergence of pertussis has been observed in the last 20 years, in spite of sustained high vaccine coverage.^[1](#CIT0001)-[3](#CIT0003)^ Hypotheses to explain this reemergence are post-vaccination waning immunity; reduced effectiveness of acellular vaccines; implementation of molecular methods for diagnosis; improvement of surveillance systems; enhanced disease awareness; and genetic changes in the pathogen.^[2](#CIT0002)^ The reemergence of epidemics, severe infections in very young not yet vaccinated infants, and pertussis in older children, adolescents and adults, resulted in renewed attention of the public health authorities to further improve pertussis control and optimize protection through vaccination.^[2](#CIT0002)^

Tetanus--diphtheria--acellular pertussis vaccines (Tdap) for adolescents and adults were licensed in 2005 and additional immunization strategies were proposed: 1) booster doses for adolescents and adults; 2) cocooning strategy; 3) pregnant women and post-partum maternal vaccination; and 4) vaccination of healthcare workers.^[2](#CIT0002)^

Pertussis among infants frequently presents as severe cases, with higher hospitalization and case-fatality rates.^[4](#CIT0004)-[6](#CIT0006)^ Cocooning and pregnant women vaccination aim to avoid pertussis among infants aged less than one year, particularly infants younger than two months, who have not received any vaccine dose. Cocooning strategy is vaccinating neonates' contacts, potentially reducing household transmission and preventing infant infection. Pregnant women vaccination results in direct newborn protection through transplacental antibody transfer from mother to infant.^[7](#CIT0007)-[9](#CIT0009)^

Even though the health benefits of some of these pertussis vaccination strategies have been demonstrated,^[7](#CIT0007),[8](#CIT0008),[10](#CIT0010),[11](#CIT0011)^ national health authorities must also consider economic aspects when deciding to recommend and fund new programs. Economic evaluation of vaccination programs may support decision-making, and is considered an essential tool in a context of rising budget constraints.^[12](#CIT0012)^

Health economic evaluation depends on good quality data of the disease epidemiology, not easily available in this case. Pertussis burden is underestimated by the surveillance systems, due to limited demand/access to healthcare, cases' underrecognition or misdiagnosis, and underreporting.^[5](#CIT0005)^ Higher rates of underreporting have been observed in older children, adolescents and adults.^[13](#CIT0013)^

Despite the methodological difficulties, the efficiency of pertussis vaccination strategies has been evaluated in several studies worldwide. The objectives of this article are to provide a critical literature review of economic evaluations of adolescents and adults' pertussis vaccination, to investigate the studies results' disparity and the reasons for such differences, and to identify most cost-effective vaccination strategies. This review attempts to provide guidance and suggestions for improvement, contributing to future economic evaluations.

Results {#S0002}
=======

Search results {#S0002-S2001}
--------------

The initial searches identified 1,318 articles. After duplicates removal and the titles and abstracts reading, 33 studies were considered potentially relevant and retrieved in full text. After reading the full text, 27 studies met the eligibility criteria and were included in this review ([Figure 1](#F0001)).10.1080/21645515.2018.1509646-F0001Figure 1.Flowchart of selection of studies included in the review.

Methodological studies characteristics {#S0002-S2002}
--------------------------------------

[Table 1](#T0001) describes the methodological characteristics of economic evaluations of pertussis immunization programs for adolescents and adults. Most studies considered developed countries: 12 in the United States of America, four in the Netherlands, three in Canada, two in England, and one each in Australia, Germany, Italy, Japan, and Spain. Only one referred to a developing country (Brazil).10.1080/21645515.2018.1509646-T0001Table 1.Methodological characteristics of the economic evaluations of pertussis vaccination for adolescents and adults.Study/ CountryYearTargeted populationVaccination strategies comparedType of studyPerspectiveModelTime horizonMonetary unit / yearHealth outcomesDiscount rateEdmunds *et al*./ England and\
Wales^[14](#CIT0014)^2002Pre-school\
Adolescents(0) no vaccination; (1) vaccination at 4 years of age; (2) Adolescents vaccinationCEAHealthcare\
provider and\
societalDynamicLifetimeUK£, 1999/2000LYGC and B -- 3%Scuffham e McIntyre/ Australia^[15](#CIT0015)^2004Both parents after birth (cocooning) and neonates(0) childhood vaccination; (1) at-birth immunization; (2) 1-month vaccination; (3) CocooningCEAHealthcare\
systemMarkov6 monthsAUS\$, 2000DALYB -- 3%Purdy *et al./* USA^[16](#CIT0016)^2004Adolescents, adults (different ages) and healthcare workers(0) no vaccination; (1) Adolescents vaccination; (2) Adults aged \>20 years; (3) Adults aged \>50 years; (4) Adults aged ≥18 years with chronic obstructive pulmonary disease; (5) Adults aged ≥15 years caretakers of infants \<1 year of age; (6) Healthcare workers vaccination; (7) 10-year boostersCBASocietalNR10 yearsUS\$, 2002Cases preventedC and B -- 3%Iskedjian *et a*l./ Canada (Ontario)^[17](#CIT0017)^2004Adolescents (12 years of age)(0) No vaccination; (1) Adolescents vaccinationCEAMinistry of Health and\
societalDynamic10 yearsCAD\$, 2003Cases preventedC -- 3%Caro *et al./* USA^[18](#CIT0018)^2005Adolescents\
(11--18 years)(0) no vaccination; (1) Adolescents vaccinationCEAHealthcare\
payer and\
societalCohort\
SimulationLifetimeUS\$, 2002LYGB -- 3%Iskedjian *et al*./ Canada (Quebec)^[19](#CIT0019)^2005Adolescents\
(14 years of age)(0) no vaccination; (1) Adolescents vaccinationCEAMinistry of Health and\
societalDynamic10 yearsCAD\$, 2003Cases preventedC -- 3%Lee *et al./* USA^[20](#CIT0020)^2005Adolescents (11 years of age); adults (20 years of age); mothers immediately after birth and all other close contacts before the birth (cocooning)(0) no vaccination; (1) Adolescent vaccination; (2) one-time adult vaccination; (3) adult vaccination with 10-year boosters; (4) Adolescent + adult + 10-year boosters; (5) CocooningCEAHealthcare\
payer and\
societalMarkovLifetimeUS\$, 2004Cases prevented and QALYC and B -- 3%Calugar et al./ USA^[21](#CIT0021)^2006Healthcare workers(0) No vaccination; (1) Healthcare workers vaccinationCBAHospital perspectiveDynamic10 yearsUS\$, 2004Exposures to pertussis cases preventedC and B -- 3%Lee *et al*./ USA^[22](#CIT0022)^2007Adults(0) No vaccination; (1) Adult vaccination; (2) 10-year boostersCEASocietalMarkovLifetimeUS\$, 2005Cases prevented and QALYC and B -- 3%Lee *et al*./ Germany^[23](#CIT0023)^2008Adults(0) No vaccination; (1) One-time adult vaccination at 20--64 years of age; (2) 10-year boostersCEAHealthcare\
payer and\
societalMarkovLifetime€, 2006Cases prevented and QALYC and B -- 3%Coudeville *et al*./ USA/ 2009^[24](#CIT0024)^2009Adolescents, adults and both parents after birth (cocooning)(0) No vaccination; (1) Adolescents vaccination; (2) Adolescents vaccination + cocooning; (3) Adolescents + adult + cocooning; (4) Adolescents + adults + 10-year boostersCEASocietalDynamic100 yearsUS\$, 2006LYGC and B -- 3%Westra *et al*./ Netherlands^[25](#CIT0025)^2010Father before and mother after the delivery (cocooning), pregnant women and neonates(0) No vaccination; (1) Vaccination at birth; (2) Cocooning; (3) Pregnant women; (4) combining (2)+(3)CEAHealthcare\
payer and\
societalDecision-tree8 years€ and US\$, 2008 (1 € = 1.4 US\$)QALYC -- 4%,\
B -- 1.5%de Vries *et al*./ Netherlands^[26](#CIT0026)^2010Adolescents\
(12 years of age)(0) No vaccination\
(1) Adolescents vaccinationCEASocietalDynamic25 years€, 2008QALYC -- 4%,\
B -- 1.5%Greer and Fisman/ Canada^[27](#CIT0027)^2011Healthcare workers(0) No vaccination; (1) Healthcare workers vaccinationCEASocietalMarkov10 yearsUS\$, 2008QALYB -- 3%Rozenbaum *et al*./ Netherlands^[28](#CIT0028)^2012Adolescents and adults(0) No vaccination; (1) A single dose for adolescents or adults; (2) single dose for both adolescents and adults vaccination; (3) booster doses with 10-year intervalsCEASocietalDynamic25 years€, 2011QALYC -- 1.5%,\
B -- 4%Itatani *et al*./ Japan^[29](#CIT0029)^2013Adolescents, adults and both parents after birth (cocooning)(0) No vaccination; (1) Adolescents vaccination; (2)\
Adolescents + 10-year booster; (3) Adolescents + cocooningCEASocietalMarkov40 yearsYenQALYC and B -- 3%Meregaglia *et al*./ Italy^[30](#CIT0030)^2013Both parents and other close contacts during pregnancy or immediately after delivery (cocooning)(0) No vaccination; (1) CocooningCEA\
CBANational Health ServiceNR1 year€, 2011Cases preventedNot consideredDing *et al*./ USA^[31](#CIT0031)^2013Mothers after birth(0) No vaccination;\
(1) Postpartum maternal vaccinationCBAHealthcare\
system and\
societalDecision tree10 yearsUS\$, 2012Cases and deaths preventedC -- 3%Terranella *et al*./ USA^[32](#CIT0032)^2013Mothers immediately after birth, all other close contacts vaccinated before the birth (cocooning) and pregnant women(0) No vaccination;\
(1) Pregnant women; (2) Postpartum maternal vaccination; (3) CocooningCEASocietalMarkov1 yearUS\$, 2011Cases averted,\
QALY and LYGC and B -- 3%Lugnér *et al*./ Netherlands^[33](#CIT0033)^2013Both parents after birth (cocooning), pregnant women and neonates(0) No vaccination;\
(1) neonate immunization at birth; (2) cocooning; (3) Pregnant women.CEASocietalNR10 years€, 2009QALYC -- 4%,\
B -- 1.5%McGarry *et al*./ USA^[34](#CIT0034)^2013Adults aged ≥65 years(0) No vaccination; (1) Adults vaccinationCEAHealthcare\
payer and\
societalDecision tree35 yearsUS\$, 2010Cases prevented and QALYC and B -- 3%McGarry *et al*./ USA^[35](#CIT0035)^2014Adults aged ≥65 years(0) No vaccination; (1) Adults vaccinationCEAHealthcare\
payer and\
societalDynamicLifetimeUS\$, 2010QALYB -- 3%Fernández-Canoa *et al*./ Spain^[36](#CIT0036)^2015Both parents after birth (cocooning) and pregnant women(0) No vaccination; (1) Cocooning; (2) Pregnant womenCBAHealthcare\
systemDecision tree1 year€, 2012Hospitalizations and cases preventedNot consideredKamiya et al./ USA^[37](#CIT0037)^2016Adolescents and adults(0) No revaccination; (1) Adolescent revaccination; (2) Adult revaccinationCEASocietyDecision tree20 yearsUS\$, 2010Cases prevented and QALYC and B -- 3%Atkins et al./ USA^[38](#CIT0038)^2016Adults, both parents (cocooning) and pregnant women(0) No vaccination; (1) Adult vaccination; (2) Mother antepartum and (3) postpartum vaccination; (4)Both parents antepartum and (5) postpartumCEAHealthcare\
providerDynamic20 yearsUS\$, 2013QALYC and B -- 3%Sartori et al./ Brazil^[39](#CIT0039)^2016Pregnant women(0) No vaccination; (2) Pregnant womenCEAHealthcare\
system and\
societalDecision tree1 yearUS\$, 2011Cases and deaths prevented and LYGNot consideredHoek et al./ England^[40](#CIT0040)^2016Pregnant women(1) No vaccination; (2) Pregnant womenCEAHealthcare\
payerDynamic5, 10, 30 and 200 yearsUK£ (reference year not reported)QALYC -1.5%, B - 3.5%[^2]

The studies evaluated 7 different strategies involving Tdap vaccine: 1) adolescents vaccination; 2) adults vaccination; 3) healthcare workers vaccination and its impact on hospital outbreak control; 4) cocooning; 5) pregnant women vaccination; 6) postpartum maternal vaccination; and 7) adults with chronic obstructive pulmonary disease.

Adolescents and adults immunization were the most frequent strategies evaluated: 11/27 each. The adults vaccination strategies were: one-time vaccination at 20 to 64 years of age (8/11), decennial boosters (6/11), and vaccination at 65 years of age or older (2/11). Six studies evaluating adolescents' immunization were published from 2002 to 2005.

The economic evaluations of Tdap considered different strategies as cocooning: vaccinating both parents immediately after birth; or assuming that fathers would be vaccinated during the pregnancy and mothers would be vaccinated immediately after delivery; or vaccinating mothers and another adult caregiver after birth; or vaccinating mothers immediately after birth and all other close contacts before the birth; or vaccinating both parents and other close contacts during pregnancy or immediately after delivery.

The first study evaluating pregnant women immunization was published in 2010. This strategy and cocooning were the most frequent strategies evaluated since then (7 studies each), followed by adult immunization (6), adolescents (4), postpartum maternal vaccination (3), and health professionals (1).

Ten studies used dynamic models, which were more frequently used to evaluate adolescents vaccination (6), followed by adults vaccination (4), cocooning (2), pregnant women (2), and health professionals vaccination (1). Thirteen studies used static models: seven used Markov, and six used decision tree. Most of them evaluated cocooning, and/or adults vaccination (6 each), followed by pregnant women vaccination (4), adolescents (3), postpartum maternal vaccination (2), and health professionals (1). Three papers did not report the model used and one used cohort simulation.

Vaccines and vaccination programs assumptions {#S0002-S2003}
---------------------------------------------

Vaccines and vaccination programs data are presented in [Table 2](#T0002).10.1080/21645515.2018.1509646-T0002Table 2.Characteristics of vaccines and vaccination programs used in the economic evaluations of pertussis vaccination for adolescents and adults.StudyVaccine coverageVaccine efficacy /effectivenessAdverse events following immunizationDuration of protection / Waning ImmunityHerd protectionEdmunds *et al*.^[14](#CIT0014)^84%95%NC5 yearsYesScuffham e McIntyre^[15](#CIT0015)^95% (adults)Adults 75%; At birth 67%; 1-month 75%NCNCNoPurdy *et al*.^[16](#CIT0016)^40% (adolescents and adults)88%1%10 yearsNoIskedjian *et al*.^[17](#CIT0017)^95%85%NCNCNoCaro *et al*.^[18](#CIT0018)^80%85%2%10 yearsYesIskedjian *et al*.^[19](#CIT0019)^85%85%NCNCNotLee *et al*.^[20](#CIT0020)^Coverage by age: 10 years 76%; 20 years 36%; 30 years 34%; 40 years 29%; 50 years 21%; 60 years 14%; 70 years 5%; postpartum 66%100%Local reaction 2%; Systemic reaction 1%; Anaphylaxis 0.0001%15 yearsYesCalugar et al.^[21](#CIT0021)^66%71.4%Anaphylaxis 0.0001%10 yearsNoLee *et al*.^[22](#CIT0022)^20--49 years of age: 66%; 50--64 years of age: 57%87%Local reactions: 2%;\
Systemic reactions: 1%; Anaphylaxis: 0,0001%15 yearsYesLee *et al*.^[23](#CIT0023)^Coverage by age: 20 years 82%; 30 years 58%; 40 years 40%; 50 years 75%; 60 years 62%87%Local reactions 2%.\
Systemic reactions 1%. Anaphylaxis 0,0001%15 yearsYesCoudeville *et al*.^[24](#CIT0024)^Adolescents 75%; adults 40%; cocooning 65%92%Additional medical consultations for AEFI (2%) in vaccination cost12 yearsYesWestra *et al*.^[25](#CIT0025)^96%89%NC4 months (persistence of maternal antibodies in infants)Node Vries *et al*.^[26](#CIT0026)^96%89%NCTwo scenarios: 8 and 15 yearsYesGreer and Fisman^[27](#CIT0027)^25 to 95%100%Anaphylaxis 0.00001%NCNoRozenbaum *et al*.^[28](#CIT0028)^70%89%NC10 yearsYesItatani *et al*.^[29](#CIT0029)^11--12 years of age 70%;\
\>12 years 20%85%Severe (anaphylaxis) 0.0001%; moderate 2%10 yearsNoMeregaglia *et al*.^[30](#CIT0030)^NR89%NCNCNoDing *et al*.^[31](#CIT0031)^25 to 60%80%Local reaction 2%;\
Systemic reaction 1%;\
Anaphylaxis 0.0001%10 yearsNoTerranella *et al*.^[32](#CIT0032)^72%Adults vaccination: 85%; Efficacy of maternal vaccination on newborn protection 60%NC2 months (persistence of maternal antibodies in infants)NoLugnér *et al*.^[33](#CIT0033)^75%89%NC5 yearsNoMcGarry *et al*.^[34](#CIT0034)^10%89%Included in the vaccine cost8 yearsNoMcGarry *et al*.^[35](#CIT0035)^10% (at 65 years of age)89%Included in the vaccine cost8 yearsYesFernández-Canoa *et al*.^[36](#CIT0036)^50%, 80% and 100%Adults vaccination: 85%\
Efficacy of maternal vaccination on newborn protection 60%NC2 months (persistence of maternal antibodies in infants)NoKamiya et al.^[37](#CIT0037)^Coverage by age: 11 years 78%; 16 years 50%; 21 years 64%74%Medically-attended allergic reactions 0.003%;\
Anaphylaxis 0.00006%15% decrease of vaccine effectiveness each year post-vaccinationNoAtkins *et al*.^[38](#CIT0038)^75%Adults vaccination: 100%;\
Maternal vaccination on newborn protection 89%US\$0.93 added to vaccination cost2.7 yearsYesSartori *et al*.^[39](#CIT0039)^57%78%NC6 months (duration of maternal antibody protection); 4 months in SANoHoek et al.^[40](#CIT0040)^60%Infants 91%;\
Mother 89%NC3 months (persistence of maternal antibodies);\
5 years among adultsNo[^3]

Ten studies that evaluated adolescents or adults vaccination considered vaccine coverage \>50%, six of them considered \>80%. Coverage varied from 20 to 96%, for cocooning, and from 57 to 96%, for pregnant women vaccination.

Ten studies clearly stated they incorporated herd protection in the model. Among them, six evaluated adolescent immunization, seven adult immunization, three cocooning, one pregnant immunization, one postpartum maternal immunization. Seven studies that evaluated adolescents and/or adults strategies did not consider herd protection.

Three studies used Markov model to evaluate adolescent and adult vaccination and considered herd protection applying a reduction factor on pertussis incidence in unvaccinated infants and adults or in the base case analysis. Caro et al. used a cohort simulation to evaluate adolescent vaccination and considered indirect impact on other age groups and on unvaccinated adolescents. Four studies that used dynamic models did not clearly state they incorporated herd protection in the model.

McGarry et al. used a dynamic model age-structured with compartments repeated for each month of age below 1 year and 1-year age groups from 1 to 99 years old. This model made possible evaluate a Tdap vaccination of adults aged 65 years in addition to DTaP vaccination from age 2 months to 4--6 years, and one dose of Tdap once to individuals 11--64 years of age in place of the decennial Td booster.

Studies that evaluated pregnant women immunization made different assumptions regarding efficacy of maternal antibodies in infant protection and duration of protection of maternal antibodies ([Table 2](#T0002)). One study considered that 60% of maternal antibodies would pass through placenta. Duration of maternal antibodies protection was assumed as two months, three months, four months and six months. Just one study considered interference of maternal antibodies in the infant response to active pertussis vaccination, assuming a negative impact (10% reduction) in the infant responses to the second and third vaccine doses.

Fourteen studies included adverse events following immunization in the model ([Table 2](#T0002)). Just three studies considered vaccine wastage rate in the model, assumed as 15%, 10% and 5%.10.1080/21645515.2018.1509646-T0003Table 3.Pertussis incidence and underreporting correction factor used in economic evaluations of pertussis vaccination for adolescents and adults.StudyIncidence rates by age groupsSource of incidence dataStrategies to account for underreportingSource of correction factorEdmunds *et al*.^[14](#CIT0014)^Consultation rates: \<3 months: 38.58/100,000; 3 months to 4 years: 107.88/100,000; 5 to 14 years: 49.27/100,000; 15 to 44 years: 5.33/100,000; \>45 years: 2.21/100,000Royal College of General Practioners Weekly Returns Service (RCGP); Hospital Episode Statistics (HES);Office of National Statistics (ONS)Used correction factor of 2.5Authors' assumptionScuffham e McIntyre^[15](#CIT0015)^5.171 notified cases / 100,000 infants per weekHealth Outcomes Information Statistical Toolkit of the New South Wales Department Australian Childhood Immunization registerNot consideredNot consideredPurdy *et al*.^[16](#CIT0016)^Adolescents and adults: 450/100,000 person-years; distribution by age: 10--19 years: 41%; 20--29 years: 7%; 30--39 years: 17%; 40--49 years: 28%Centers for Disease Control and Prevention; Acellular Pertussis Vaccine Trial (APERT) (clinical trial).Children aged 0--9 years: correction factor of 2Authors' assumptionIskedjian *et al*.^[17](#CIT0017)^Adolescents aged 12--17 years: 511/100,000; Adults aged 18--21 years: 65/100,000Health CanadaAdolescents: correction factor of 9Enhanced surveillance with serosurveyCaro *et al*.^[18](#CIT0018)^0.2--57/100,000 (age-specific rates used)Centers for Disease Control and PreventionUsed correction factor of 7.6Local study using capture-recapture methods to analyze morbidity data from independent surveillance systemsIskedjian *et al*.^[19](#CIT0019)^Adolescents (14--17 years) 511/100,000; Adults (18--24 years) 65/100,000Health CanadaUsed correction factor of 9Enhanced surveillance with serosurveyLee *et al*.^[20](#CIT0020)^Infants 58.5/100,000; Adolescents 155/100,000; Adults 11/100,000Massachusetts Department of Public Health (pertussis surveillance data)Not consideredNot consideredCalugar *et al*.^[21](#CIT0021)^Proportion of infections in healthcare workers: 6.75%Two local studiesNot consideredNot consideredLee *et al*.^[22](#CIT0022)^Incidence in adults ranged from 10 to 500/100,000;\
Infants 58.5/100,000Infants: 2 local studies; Adults: Massachusetts Department of Public Health (official data)Range of incidencesTdap efficacy study; 3 studies of pertussis prevalence among persons with coughLee *et al*.^[23](#CIT0023)^Adults 165/100,000; Adolescents 95/100,000; Infants 22/100,000.Adults: Local study (17160764); Adolescents and infants: governmental epidemiological dataAdults' Incidence varied from 50 to 500 / 100,000 in sensitivity analysisStudies in Europe and USACoudeville *et al*.^[24](#CIT0024)^Adult cases requiring medical care 90/ 100,000Acellular Pertussis Vaccine Trial (APERT) and Centers for Disease Control and Prevention (CDC)Children data were adjusted using age-specific underreporting estimates (data not shown)Capture-recapture studyWestra *et al*.^[25](#CIT0025)^Incidence in infants \<1 year of age: 129/100,000. Distribution of cases among infants \<1 year: 0 months: 7.0%;\
1 month: 21.4%; 2 months: 18.1%;\
3 months: 11.2%; 4 months: 5.3%;\
5 months: 2.7%; 6 months: 7.8%;\
7 months: 4.2%; 8 months: 8.0%;\
9 months: 5.5%; 10 months: 5.0%;\
11 months: 3.8%. Incidence in adults 25--34 years of age: 17.9/100,000Centre for Infectious Disease Control of the Dutch National; Institute for Public Health and the EnvironmentAdults: correction factor of 200\
Children: no correctionSerological survey and dynamic transmission model studyde Vries *et al*.^[26](#CIT0026)^Age specific (data not shown)RIVM report -- *Rijksinstituut voor Volksgezondheid en Milieu*Age specific correction factor of (up to 660)Serological surveyGreer and Fisman^[27](#CIT0027)^Average number of exposures/case: 8.73 Symptomatic adults: 40%Data from a real outbreakNot consideredNot consideredRozenbaum *et al*.^[28](#CIT0028)^\<1 year: 200/100,000\
5 years: 100/100,000\
≥15 years: 50/100,000Surveillance data from 1996 to 2001Used correction factor of 600Serological surveyItatani *et al*.^[29](#CIT0029)^Incidence rates ranged from 25 to 250/100,000 person-yearsJapan's Infectious Disease Surveillance CentreRange of incidencesPrevious studies from USA, Germany and CanadaMeregaglia *et al*.^[30](#CIT0030)^Infants: 54/100,000 hospitalizations/yearRegional hospital discharge databaseNot consideredNot consideredDing *et al*.^[31](#CIT0031)^Mothers -- 450/100,000.\
Infants aged \<6 months -- 71.6/100,000Mothers: local study.\
Infants: Surveillance data (California Department of Public Health and Centers for Disease Control and Prevention (CDC)Not consideredNot consideredTerranella *et al*.^[32](#CIT0032)^\<1 year: 62.6/100,000; Incidence by month of age (/100,000) \< 1: 12.4; 1: 18.9; 2: 15.3; 3: 8.9; 4: 5.7; 5: 3.2; 6: 2.4; 7: 1.6; 8: 1.5; 9: 1.4; 10: 1.1; 11: 1.4National Notifiable Diseases Surveillance System (NNDSS), 2000 -- 2007.Increase of 15%Authors' assumptionLugnér *et al*.^[33](#CIT0033)^\<5 years-old: 130/100,000;\
20 -- 40 years-old women: 2,606/100,000Statistics Netherlands100 x the surveillance dataSerological surveysMcGarry *et al*.^[35](#CIT0035)^Different incidence rates were considered: 25, 50, 100, 150, and 200/100,000Centers for Disease Control and Prevention, California Department of Public Health Pertussis Report 2011, Washington State Department of Health (2012)Different incidence rates were usedTdap efficacy study; 3 studies of pertussis prevalence among persons with coughMcGarry *et al*.^[35](#CIT0035)^Incidence rate by age (/100,000)\
\<1 year: 435.00; 1--6 years: 61.8; 7--9 years: 67.3; 10--18 years: 49.0; 19--64 years: 124.15; ≥65 years: 86.08California Department of Public Health surveillance data; Centers for Disease Control and Prevention (CDC).For adults ≥65 years,\
data was inflated, assuming 1% reporting2009 Centers for Disease Control and Prevention (CDC)Fernández-Canoa *et al*.^[36](#CIT0036)^Hospitalization by age-group\
0--2 months -- 119/100,000; 3--4 months -- 26/100,000 ; 5--6 months -- 5/100,000; 7--11 months -- 4/100,000; \<1 year -- 153/100,000Hospitalization data of Spanish Government (MBDS), from 2009 to 2011.Not consideredNot consideredKamiya *et al*.^[37](#CIT0037)^Age-specific; 11--30 years (data not shown)National Notifiable Diseases Surveillance System -- NNDSS 2002--2011Used correction factor of 20--200 in sensitivity analysisSeveral studies and authors' assumptionsAtkins et al.^[38](#CIT0038)^The model was calibrated to USA incidence data from 2003--2012 (data not shown)Centers for Disease Control and Prevention (CDC)The authors combined data of reported case, hospitalization rates, reporting rates for hospitalized cases, and active surveillance of non-hospitalized cases (data not shown)CDC, Wisconsin Department of Health Services, and local studySartori *et al*.^[39](#CIT0039)^Children aged \<1 year-old: 55.407/100,000National Notifiable Diseases Information System (Sistema de Informação de Agravos de Notificação, SINAN)Not consideredNot consideredHoek et al.^[40](#CIT0040)^Infants aged \<3 months: \~ 0.5 to \~ 45/100,000; Women aged 20 -- 44 years: 0 to \~ 40/100,000Number of hospitalization from 2010 to 2012 (NHS)Not consideredNot considered

Epidemiological estimates {#S0002-S2004}
-------------------------

[Table 3](#T0003) shows pertussis incidence estimates used in the studies. Pertussis incidences among adolescent or adults were considered in 20 of 27 studies, and 18 of them used some strategy to correct pertussis underreporting.

Ten studies used official incidence data multiplied by a correction factor, which varied from 2.5 to 660; four studies considered a range of incidences for adults or adolescents; and four studies derived pertussis incidence from local studies data. The approaches for estimating pertussis incidences among adolescents and adults and the correction factor were based on serological surveys (8 studies), clinical trials (6), authors' assumption (2), capture-recapture studies (1), enhanced surveillance (1), and compilation of data from previous dTpa economic studies (1). One study applied the infants' disease incidence to women of childbearing age. Lee et al. (2005) estimated the burden of disease among adolescents and adults in the USA based on 2003 Massachusetts State incidence data. Massachusetts was the only state in the USA that had a single-serum enzyme-linked immunosorbent assay for IgG anti-pertussis toxin available as a diagnostic test, which allows enhanced disease detection among adolescents and adults. Two studies corrected disease data for infants to take underreporting into account, using an underreporting factor of 2 and 1.15.

Pertussis incidence rates varied from 22 to 435 per 100,000, for infants, from 10 to 511 per 100,000, for adolescents, and from 5.33 to 2,606 per 100,000, for adults.

Supplementary Table 1 shows outpatient cases, hospitalizations, complications and case-fatality rates estimates. Even after correcting underreporting, most studies considered that all pertussis cases among adolescents and adults use health care services, resulting in cost. Among adolescents and adults, mild outpatient cases varied from 1% to 79.3%, while severe cases ranged from \<1% to 66%. Caro et al. and McGarry et al. assumed that 70% of unreported cases would be significantly milder than typical cases. Coudeville et al. considered 2% of infected adults would be asymptomatic and calibrated the model for their potential infectiousness. Three studies explored the impact of including asymptomatic infections in the disease transmission dynamic model.

Cost estimates {#S0002-S2005}
--------------

The elements of costs considered in the reviewed studies are described in Supplementary Table 2. All studies included direct medical costs and the vaccination program costs, and 23 included indirect costs. Calugar et al. evaluated the healthcare workers vaccination from the hospital perspective and included productivity loss as indirect cost. Atkins et al. included indirect costs in the sensitivity analysis. All the studies used local data to estimate direct medical costs, except Itatani et al., who assumed the values.

Eight studies considered public health response as part of the direct medical costs. The studies considered costs of health surveillance, contact tracing and prophylactic measures.

Seven studies that evaluated strategies focused on protecting infants (pregnant women vaccination, maternal postpartum vaccination or cocooning) considered caregivers loss of productivity.

Results of the analyses {#S0002-S2006}
-----------------------

[Table 4](#T0004) shows the summary measures presented in the results of the analyses.10.1080/21645515.2018.1509646-T0004Table 4.Summary measures (Incremental Cost-Effectiveness Ratio, ICER, or Cost-Benefit ratio) presented in results of economic evaluations of pertussis vaccination for adolescents and adults, according to the perspective.StudySocietal\*Health care provider\*SponsorEdmunds *et al*.^[14](#CIT0014)^9,278.21/LYG18,047.45/LYGMedical Research CouncilScuffham e McIntyre^[15](#CIT0015)^Not considered1,562,146.18/DALYCommonwealth Department of Health and AgeingPurdy *et AL*.^[16](#CIT0016)^Cost preventable (billions of US\$)/ break-even (US\$)\
**Adolescent vaccination**: US\$0.4 to 2.1 billons/ US\$49.12Not consideredGlaxoSmithKlineIskedjian *et al*.^[17](#CIT0017)^Cost-saving274.77/case preventedSanofi-PasteurCaro *et al*.^[18](#CIT0018)^6,322.19/LYG29,310.66/ LYGNRIskedjian *et al*.^[19](#CIT0019)^374.13/ case prevented476.35/case preventedSanofi-PasteurLee *et al*.^[20](#CIT0020)^**Adolescents vaccination**: 25,244.96/QALY;**Adolescents vaccination**: 29,031.70/QALY;National Immunization Program, Centers for Disease Control and Prevention, Association of Teachers of Preventive Medicine, National Vaccine Program Office\
Agency for Healthcare Research and QualityCalugar et al.^[21](#CIT0021)^Not consideredCost-benefit ratio: 3Centers for Disease Control and Prevention and St. Luke's HospitalLee *et al*.^[22](#CIT0022)^**Adult vaccination**: 13,539.39/ QALY; **10-year boosters**: 14,770.25/QALYNot consideredAgency for Healthcare Research and Quality, National Immunization Program, Centers for Disease Control and Prevention Association of Teachers of Preventive MedicineLee *et al*.^[23](#CIT0023)^**Adult vaccination**: 8,796.50/QALY. **10-year boosters**: 10,919.79 /QALY**Adult vaccination**: 31,919.79 /QALY. **10-year boosters**:40,949.25/QALYAgency for Healthcare Research and Quality, US Department of Health and Human ServicesCoudeville *et al*.^[24](#CIT0024)^Cost-savingNot consideredSanofi-PasteurWestra *et al*.^[25](#CIT0025)^Cost-saving**Cocooning**: 6,234.84/QALY; **Pregnant women**: 4,743.90/QALYGlaxoSmithKlinede Vries *et al*.^[26](#CIT0026)^5,988.16/QALY and 8,635.27/QALY (for duration of protection after vaccination of 8 and 15 years, respectively)Not consideredGlaxoSmithKlineGreer and Fisman^[27](#CIT0027)^Cost-savingNot consideredOntario Early Researcher Award\
Sanofi-PasteurRozenbaum *et al*.^[28](#CIT0028)^**Single (3rd) booster for adolescents or adults**: 7,292.58/QALY; **Adolescent + adult vaccination**: 13,022.47/QALY. **10-year booster**: 21,971.53 /QALYNot consideredNRItatani *et al*.^[29](#CIT0029)^**Adolescents' vaccination**: 36.24/QALY; **Adolescents + 10-year boosters**: dominated; **Adolescents + cocooning**: 2,432.54/QALY**Adolescents vaccination**: 51.21/QALY; **Adolescents + 10-year boosters**: dominated; **Adolescents + cocooning**: 2,496.61/QALYNRMeregaglia *et al*.^[30](#CIT0030)^Not considered32%: 246,490.46/case preventedNRDing *et al*.^[31](#CIT0031)^Expected Net of Benefit US\$61.25/vaccinated motherExpected Net of Benefit US\$37.25/ vaccinated motherCenters for Disease Control and Prevention, U.S. Dept. of Health and Human ServicesTerranella *et al*.^[32](#CIT0032)^**Pregnant women**: 439,708.46/QALY. **Cocooning**: 2,127,816.28/QALYNot consideredNRLugnér *et al*.^[33](#CIT0033)^**Cocooning**: 120,828.15/QALY; **Pregnant women**: 171,060.07/QALY.Not consideredNational Institute for PublicHealth and the Environment, Bilthoven, NetherlandsMcGarry *et al*.^[34](#CIT0034)^ICER per disease incidence (/100.000): 25: 369,229.63/QALY; 100: 68,896.32/QALY; 200: 18,675.26/QALY."similar results"GlaxoSmithKlineMcGarry et al.^[35](#CIT0035)^Cost-savingCost-savingGlaxoSmithKlineFernández-Canoa *et al*.^[36](#CIT0036)^Not consideredBenefit-to-cost ratio: **Cocooning**: 0.4; **Pregnant women**: 0.15.NRKamiya *et al*.^[37](#CIT0037)^**Adolescents vaccination**: 21,672,785.63/QALY\
**Adult vaccination**: 28,752,816.66/QALYNot consideredCenters for Disease Control and PreventionAtkins *et al*.^[38](#CIT0038)^Not considered**Pregnant women**: 116,902.95/QALY; Both parents: 835,056,23/QALY (antepartum) and dominated (postpartum); Adult vaccination: dominatedNotsew Orm Sands Foundation (Houston, Texas) and Sanofi-PasteurSartori *et al*.^[39](#CIT0039)^17,217.25/LYG17,237.13/LYGBrazilian Ministry of Health/Pan American Health OrganizationHoek *et al*.^[40](#CIT0040)^Not considered60,619.60/QALYNational Institute for Health\
Research Health Protection Research Unit[^4][^5]

Two studies showed that adolescents' vaccination strategy was cost-saving at society perspective. Other seven studies had incremental cost-effectiveness ratio considered cost-effective or highly cost-effective and recommended it as a good strategy. Adolescent vaccination presented unsatisfactory results in only one study.

Among 11 studies that evaluated adults vaccination strategy, the program was considered cost-effective in six and cost-saving in two.

Cocooning strategy performance diverged among studies. It was cost-saving in two studies, and not cost-effective in the other studies, with ICER ranging from U\$112,091/QALY to U\$2,005,940/QALY.

Seven studies evaluated pregnant women vaccination and the ICER varied from cost-saving to not cost-effective (US\$ 439,708.46/QALY). When compared with cocooning, pregnant women vaccination had better economic performance in four of five studies.

Ten studies declared sponsorship by pharmaceutical industry; eleven by public institutions and six did not report sponsorship. All studies sponsored by pharmaceutical industry showed good results for Tdap vaccination, except two that evaluated cocooning, pregnant women and elderly vaccination. All cost-saving studies were in this group.

All studies conducted some Sensitivity Analyses (Supplementary Table 3). The parameters with the greatest impact on the results were pertussis incidence, followed by vaccine efficacy and vaccine price.

Discussion {#S0003}
==========

The first Tdap economic evaluation was published in 2002, when a significant increase in pertussis incidence among unvaccinated infants, adolescents and adults became a problem in developed countries and new immunization strategies for older age groups became available.^[14](#CIT0014),[41](#CIT0041)^ Adolescents and adults vaccination were the first strategies introduced in developed countries, such as Australia, Canada, France, Germany and the USA,^[2](#CIT0002)^ and also the first economically evaluated.

In general, the studies found favorable cost-effectiveness ratio for adolescents and adults vaccination, particularly for adolescents' vaccination. Assumptions regarding underreporting correction, herd protection and vaccine coverage were crucial to cost-effectiveness results of adolescents and adults vaccination.

In general, pertussis is considered a childhood disease and goes unnoticed among adolescents and adults. Adolescents and adults usually have milder symptoms, similar to viral infections, making pertussis diagnosis difficult.^[42](#CIT0042),[43](#CIT0043)^ Mostly, only culture-positive cases or cases with typical symptoms are reported. Underreporting is an issue since asymptomatic infections are transmissible.^[5](#CIT0005),[43](#CIT0043)^ Most studies on the cost-effectiveness of adolescent and adults vaccination explicitly took underreporting into account, increasing the incidence detected by regular health surveillance from 2.5 to 600 times. Serological surveillance studies, capture-recapture studies, enhanced surveillance data and author assumption were the source for correction factor. Increasing the incidence has a positive impact on the performance of the strategies evaluated.^[17](#CIT0017),[19](#CIT0019),[20](#CIT0020),[26](#CIT0026),[28](#CIT0028)^

Some studies considered that all pertussis cases used health services resulting in direct costs. Assuming that undiagnosed or unreported cases are just as severe and costly as reported cases probably overestimates pertussis-related health resource utilization and costs. Few studies considered asymptomatic cases and recognized their importance in the transmission of the disease.^[24](#CIT0024),[26](#CIT0026),[28](#CIT0028),[34](#CIT0034),[35](#CIT0035)^

Eleven studies that evaluated adolescents or adults vaccination considered herd protection.^[14](#CIT0014),[17](#CIT0017),[19](#CIT0019),[20](#CIT0020),[22](#CIT0022),[24](#CIT0024),[26](#CIT0026),[28](#CIT0028),[29](#CIT0029),[35](#CIT0035),[38](#CIT0038)^ Eight of them used dynamic models and three studies used static models and included herd protection as a correction factor. Herd protection refers to protection of susceptible individuals due to decreased transmission of the pathogen, i.e., reduction in the force of infection, when a high proportion of the population is immunized. Dynamic models allow projecting changes in transmission patterns, taking herd protection into account. Adolescents and adults are the main source of pertussis infection for infants.^[2](#CIT0002),[4](#CIT0004),[44](#CIT0044)-[48](#CIT0048)^ Considering herd protection for adolescents and adults vaccination would result in averted cases among infants. However, recent studies showed the lack of sterilizing mucosal immunity following aP vaccination.^[49](#CIT0049)^ The vaccinated could be colonized by *Bordetella pertussis* and transmit the disease, lacking herd protection of adolescents and adults vaccination.^[49](#CIT0049)^

Some economic evaluations of adolescents and adults vaccination overestimated vaccine coverage, reaching 96%, which contributed to the good performance of the program. Vaccination coverage among adolescents and adults is low for many vaccines in most countries. In the USA, Tdap vaccine coverage among adults aged 19--64 years was 24.7%, in 2014--2015.^[50](#CIT0050)^ According to the Vaccine European New Integrated Collaboration Effort consortium, adult vaccination coverage for tetanus and diphtheria ranged from 61% to 74%, in 2010--2011.^[51](#CIT0051)^ In Brazil, dT coverage among adults is approximately 33% per year (Immunization Division, São Paulo State) and Tdap coverage among pregnant women was 40.3%, in 2015.

The primary objective of the cocooning and pregnant women vaccination is to reduce transmission to infants. The first economic study of cocooning was published in 2004.^[15](#CIT0015)^ Cocooning was introduced in developed countries, such as Australia, France, Germany and the USA, in the early 2000s.^[2](#CIT0002)^ This review showed that cocooning performance diverges among studies. The economic evaluations with higher effectiveness for cocooning,^[23](#CIT0023),[33](#CIT0033)^ even to the point of cost-saving,^[24](#CIT0024)^ assumed that the mother was the only source of pertussis for the infants, overestimating the impact of postpartum maternal vaccination.

Cocooning effectiveness/impact also diverged among different studies, and there is evidence that the strategy is inefficient to reduce hospitalizations and deaths among infants in settings with low pertussis incidence. In Canada, it would be necessary to vaccinate more than 10,000 people to prevent one hospitalization, and vaccinate at least 1 million to prevent one death of infant \<1 year of age, in a setting with 57 hospitalizations per 100,000 inhabitants and risk of parents-to-infant transmission of 35%.^[52](#CIT0052)^ In the USA, a study of a postpartum vaccination program did not show any beneficial effect.^[53](#CIT0053)^

After a frustrating performance of the previous strategies, pregnant women vaccination was introduced in USA, in 2011, and UK, in 2012. The first economic evaluation was published in 2010, when many countries reported further increase of pertussis incidence in infants.^[3](#CIT0003),[54](#CIT0054),[55](#CIT0055)^ Pregnant women vaccination was demonstrated efficacious, had good economic performance and became the main strategy of adults' pertussis vaccination to protect infants.

The overall impact and cost-effectiveness of cocooning are likely to be substantially lower than pregnant women vaccination, which requires only one dose, whereas cocooning requires, as a minimum, multiple doses for parents and family members. Implementing an effective cocooning strategy with high coverage has also proved challenging in several countries.^[2](#CIT0002)^

Pertussis incidence was one of the parameters that mostly influenced the results of pregnant women vaccination programs. Westra et al. (2010)^[25](#CIT0025)^ reported that ICERs increased 6x and 3x for cocooning and pregnant women vaccination, respectively, when unreported cases were not taken into account in the analysis. Van Hoek et al.^[40](#CIT0040)^ show that pregnant women pertussis immunization would be highly cost effective if the peak incidence of infant disease at the time the program was introduced continues (ICER \~ 17,000 during incidence peak). However, the ICER was highly dependent on the future incidence of pertussis in infants under 3 months of age and it will vary over time considering the cyclical pattern of the disease.^[40](#CIT0040)^

The number of vaccinees in cocooning and pregnant women vaccination does not allow the development of herd protection and static models are adequate to evaluate these strategies.^[25](#CIT0025),[39](#CIT0039)^

Only eight studies included the public health response in the direct costs.^[17](#CIT0017)-[19](#CIT0019),[21](#CIT0021),[27](#CIT0027),[32](#CIT0032),[36](#CIT0036),[39](#CIT0039)^ In one study in the USA, the epidemiological investigation of household contacts, laboratory testing the symptomatic contacts and antibiotic treatment for contacts positive for *B. pertussis* cost US\$2,269/case, being an important component of costs.^[32](#CIT0032)^ Another study, in Brazil, estimated that surveillance costs per case were higher than the outpatient care costs per case.^[39](#CIT0039)^ Many countries have long-standing surveillance systems for pertussis.^[56](#CIT0056)^ The case reporting results in a public health response, including cases interviews, contacts testing (PCR or culture), identification of symptomatic contacts, and treatment of symptomatic contacts or chemoprophylaxis for all contacts. The U.S. Centers for Disease Control and Prevention recommends post exposure prophylaxis for all household contacts of a pertussis case.^[57](#CIT0057)^ In Brazil, the MoH recommends nasopharyngeal swab for diagnostic tests for all domiciliary contacts of pertussis cases.^[58](#CIT0058)^ The contact tracing results in costs that should be considered in economic evaluation of pertussis vaccination programs.

Just one study referred to a developing country.^[54](#CIT0054)^ Pregnant women vaccination was shown a cost-effective intervention for preventing pertussis cases and deaths in infants in Brazil. Brazil, Argentina and Chile reported significant increase in pertussis incidence rates in recent years, despite pertussis childhood vaccination with whole-cell vaccines and have already introduced pregnant women vaccination with Tdap.^[3](#CIT0003),[54](#CIT0054)^

This systematic review and synthesis of the results of the articles included in the analysis of economic evaluations of pertussis vaccination strategies in adults presented more challenges than usual in this type of study due the large number of different strategies, and methodological differences of the studies. The strategies performance and economic evaluation conclusions varied considerably among different studies. Variations were due to different assumptions on epidemiological parameters, health service utilization and costs made in the studies from different countries. Understanding the model and all the parameters used in the economic analysis is essential to understand the results, and identify the major issues important to public health decisions.

Methods {#S0004}
=======

Protocol and registration {#S0004-S2001}
-------------------------

This systematic review has been conducted based on the Centre for Reviews and Dissemination (CRD) guidelines^[12](#CIT0012)^. A protocol was developed before initiating this review but it was not registered in the international prospective register of systematic reviews (PROSPERO).

Literature search {#S0004-S2002}
-----------------

A search of studies published from January 1st, 2000 to July 15th, 2016 was conducted in four databases: MEDLINE (via PubMed), Excerpta Medica, CRD and Latin-American and Caribbean Health Sciences Literature (LILACS). It was deemed appropriate to narrow the search to this timeframe because Tdap was licensed in 2005.The following terms were used: 'pertussis' and 'pertussis vaccine' in combination with any of the following: 'economics', 'pharmaceutical', 'cost analysis', 'cost of illness', 'cost(-) benefit', 'health care cost", 'cost(-) effectiveness', 'cost(-)utility', 'cost' and/or (pharmaco) economic evaluation. The search was limited to full economic evaluations on pertussis vaccination of adolescents (≥10 years of age) and adults. The Appendix 1 shows the electronic search strategies created for each database.

Searching other sources {#S0004-S2003}
-----------------------

The reference lists of all included studies identified in the electronic databases were reviewed to identify further studies.

Eligibility criteria {#S0004-S2004}
--------------------

The eligibility criteria were defined based on the components of the PICOS approach: Population: adolescents (≥10 years of age) and adults (including healthcare workers, pregnant women, cocooning and any other vaccination strategies targeting adolescents or adults);Intervention: pertussis vaccination;Comparators: no vaccination and strategies of pertussis vaccination of adolescents and adults;Outcome: incremental cost-effectiveness ratio (ICER) or cost-benefit ratio;Study design: full economic evaluation, defined as a comparative analysis of costs and consequences of two alternative healthcare interventions; including cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis.

Study selection {#S0004-S2005}
---------------

One reviewer (EGF) screened all titles and abstracts of studies retrieved by the search and selected them using the eligibility criteria. Any doubts during this process were resolved by discussion with another reviewer (PCS).

Data extraction {#S0004-S2006}
---------------

A predefined data extraction form was calibrated amongst the two reviewers (EGF and CCMR) using a random sample of five included studies. After this, data was independently extracted by the two reviewers (EGF and CCMR) and checked by them. The divergences between the data that the reviewers extracted were resolved by discussion or by arbitrage of a third reviewer (PCS).

Data collected {#S0004-S2007}
--------------

Methodological characteristics: type of study, perspective, model, herd protection, time horizon, number of cohorts, currency and year of costs, discount rate, sensitivity analysis, and parameters varied in the sensitivity analysis;Estimates of key parameters: epidemiological data (pertussis incidence, disease severity, and case fatality rate); vaccine related data (vaccination schedule, coverage, efficacy, adverse events, and waning immunity rate); costs (direct and indirect), and summary measures (incremental cost-effectiveness ratios (ICERs) or cost-benefit ratio);Research funding sources.

To improve comparability between studies results, all summary measures presented in different currencies were adjusted to 2016 value (latest price year used in included studies) using consumer price index \[59\]. Afterwards, they were converted to international dollar units using Purchasing Power Parity (PPP), the exchange-rate equivalent to an identical basket of goods and services in countries (Organization for Economic Co-operation and Development.^[60](#CIT0060)^

Synthesis of results {#S0004-S2008}
--------------------

The more relevant results were summarized as a narrative synthesis. The methodological characteristics and key variables estimates are shown in summary tables.
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###### Supplemental Material

10.1080/21645515.2018.1509646-UT0001DatabaseSearch strategyMEDLINE((((((((((((((((((((((((((Economics\[MeSH Terms\]) OR Economics, Pharmaceutical\[MeSH Terms\]) OR ((cost and cost analysis\[MeSH Terms\]))) OR cost of illness\[MeSH Terms\]) OR cost benefit analyses\[MeSH Terms\]) OR health care cost\[MeSH Terms\]) OR analyses, cost benefit\[MeSH Terms\])) OR ""analysis cost-benefit"") OR ""cost benefit analysis"") OR ""analyses, cost benefit"") OR ""analysis, cost benefit"") OR ""cost benefit analyses"") OR ""cost effectiveness"") OR ""effectiveness, cost"") OR ""cost-utility analysis"") OR ""analysis, cost-utility"") OR ""cost utility analysis"") OR ""economic, evaluation"") OR ""evaluation economic"") OR ""cost benefit"") OR ((""cost and benefit""))) OR ((""benefit and cost""))) OR ""cost effectiveness-analysis"") OR ""analysis, cost-effectiveness"") OR ""cost effectiveness analysis"")) AND ("pertussis" OR pertussis\[MeSH Terms\] OR pertussis vaccine\[MeSH Terms\] OR "pertussis vaccine" OR "Diphtheria-Tetanus-acellular Pertussis Vaccines" OR ""Diphtheria-Tetanus-acellular Pertussis Vaccines""\[MeSH Terms\])EMBASE('diphtheria pertussis tetanus vaccine' OR 'pertussis' OR 'pertussis vaccination' OR 'pertussis vaccine') AND ('biomedical technology assessment'/exp OR 'cost utility analysis'/exp OR 'cost of illness'/exp OR 'cost minimization analysis'/exp OR 'pharmacoeconomics'/exp OR 'cost benefit analysis'/exp)CDR(PERTUSSIS) OR (PERTUSSIS VACCINE) OR (Diphtheria-Tetanus-acellular Pertussis Vaccines) IN DARE, NHSEED, HTALilacs((tw:(Pertussis Vaccine)) OR (tw:(Diphtheria-Tetanus-Pertussis Vaccine)) OR (tw:(Whooping Cough)) OR (tw:(Diphtheria-Tetanus-acellular Pertussis Vaccines)) AND (tw:(Pharmaceutical Economics)) OR (tw:(Pharmacoeconomics)) OR (tw:(Cost-Benefit Analysis)) OR (tw:(Cost-Effectiveness Evaluation)) OR (tw:(cost effectiveness)))

[^1]: PCS, HMDN and AMCS are researchers from the IATS, National Institute of Science and Technology for Health Technology Assessment (IATS) -- CNPq/Brazil.

[^2]: C: Costs; B: Benefits; CEA: cost-effectiveness analyses; CBA: cost-benefit analyses; CUA: cost-utility analyses; LYG: life year gained; QALY: quality-adjusted life year; LYG: Life of years gained; NR: Not Reported

[^3]: NC -- Not Considered; NR -- not reported: SA -- Sensitivity analyses; AEFI - adverse event following vaccination

[^4]: \*Summary measures were adjusted to 2016 values and then converted to international dollar units using Purchasing Power Parity (PPP).

[^5]: NR: Not reported; LYG: Life years gained; QALY: Quality adjusted life years; DALY: Disability adjusted life year
